European Association of Urology Annual Congress (EAU22)

Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa

Roshini Claire Anthony, 20220825180001

Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.

Is 5-year interval sufficient for prostate cancer screening in older men?

Roshini Claire Anthony, 20220818180001

Diagnosis, progression, or death due to prostate cancer occur at approximately a decade to 15 years following an initial assessment of prostate-specific antigen (PSA) levels in older men, according to a study presented at EAU 2022.

Methenamine hippurate as good as antibiotic prophylaxis for recurrent UTI

Elvira Manzano, 20220810000000

Daily antibiotics are the current guideline-recommended standard for urinary tract infection (UTI). Interestingly, in the randomized, open-label ALTAR trial presented at EAU 2022, the urinary antiseptic methenamine hippurate was noninferior to antibiotic prophylaxis in women with recurrent UTI.

Avelumab benefit may extend to cisplatin-unfit bladder cancer patients

Audrey Abella, 20220808100000

The anti-PD-L1 antibody avelumab demonstrated clinical activity as first-line treatment for patients with metastatic or locally advanced urothelial carcinoma who were PD-L1-positive and ineligible for cisplatin, according to findings from the ARIES trial presented at EAU 2022.

Abiraterone-olaparib confers clinical benefit for mCRPC patients

Audrey Abella, 20220804100000

The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.

Patients prefer being awake but sedated during urologic procedures

Elvira Manzano, 20220804000000

Patients prefer conscious sedation over general anaesthesia (GA) during urologic procedures, according to Canadian researchers who followed patients undergoing various endourologic, ureteric, urethral, or advanced cystoscopic procedures.

Which drugs raise risk of urinary tract infections?

Stephen Padilla, 20220729120000

Some medications may directly cause the occurrence of urinary tract infections (UTIs), and a recent study presented at the 37th Annual European Association of Urology Congress (EAU 2022) has identified six drugs that appear to contribute to “significant reporting levels” for infections.

SOUNDS: Real-world use affirms efficacy, safety of sacral neuromodulator device for OAB

Jairia Dela Cruz, 20220728200000

Delivering electric stimulation to the sacral nerves using an implantable device appears to be safe and effective in the treatment of overactive bladder (OAB) in a real-world setting, according to the France-based SOUNDS study presented at the 37th Annual European Association of Urology Congress (EAU 2022).

Verapamil reduces penile curvature, plaque size in Peyronie’s disease

Stephen Padilla, 20220728120000

Use of the calcium channel blocker verapamil is both safe and effective for the treatment of Peyronie’s disease, as proven by a decrease in penile curvature, reduction in plaque size, and improvement in erectile dysfunction, with minimal to mild side effects, relative to placebo, according to the results of a systematic review and meta-analysis.

Short-course quinolones, pivmecillinam on par with standard regimens in uncomplicated cystitis

Jairia Dela Cruz, 20220727140000

For women with acute uncomplicated cystitis, treatment regimens that include third- and fourth-generation quinolones and pivmecillinam can be administered in shorter courses, which perform similarly to the currently recommended regimens in terms of achieving symptomatic cure, according to the results of a meta-analysis presented at the 37th Annual European Association of Urology (EAU) Congress.